PNC Financial Services Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,537
| Closed | -$15.3K | – | 5155 |
|
|
2025
Q2 | $15.3K | Buy |
1,537
+729
| +90% | +$5.87K | ﹤0.01% | 3693 |
|
|
2025
Q1 | $4.82K | Buy |
808
+790
| +4,389% | +$5.8K | ﹤0.01% | 4079 |
|
|
2024
Q4 | $138 | Sell |
18
-52
| -74% | -$447 | ﹤0.01% | 4689 |
|
|
2024
Q3 | $715 | Hold |
70
| – | – | ﹤0.01% | 4506 |
|
|
2024
Q2 | $1.04K | Buy |
70
+11
| +19% | +$158 | ﹤0.01% | 4414 |
|
|
2024
Q1 | $805 | Hold |
59
| – | – | ﹤0.01% | 4415 |
|
|
2023
Q4 | $646 | Sell |
59
-2,228
| -97% | -$22.1K | ﹤0.01% | 4374 |
|
|
2023
Q3 | $25K | Buy |
2,287
+1,299
| +131% | +$16.6K | ﹤0.01% | 3311 |
|
|
2023
Q2 | $13.1K | Buy |
988
+728
| +280% | +$10.4K | ﹤0.01% | 3751 |
|
|
2023
Q1 | $3.54K | Sell |
260
-1,427
| -85% | -$25.6K | ﹤0.01% | 4153 |
|
|
2022
Q4 | $32.9K | Sell |
1,687
-282
| -14% | -$5.51K | ﹤0.01% | 3221 |
|
|
2022
Q3 | $37K | Buy |
1,969
+358
| +22% | +$8.25K | ﹤0.01% | 3144 |
|
|
2022
Q2 | $34K | Buy |
1,611
+1,048
| +186% | +$24.9K | ﹤0.01% | 3218 |
|
|
2022
Q1 | $18K | Buy |
+563
| New | +$20.5K | ﹤0.01% | 3621 |
|
|
2021
Q2 | – | Sell |
-5
| Closed | – | – | 4232 |
|
|
2021
Q1 | $0 | Buy |
+5
| New | +$181 | ﹤0.01% | 4154 |
|
Other funds holding ITOS
PNC Financial Services Group's ITOS Position: Q3 2025 in Review
PNC Financial Services Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 1,537 shares — an estimated $15.3K sold.
PNC Financial Services Group first reported a position in ITOS in Q1 2021 and held it in 15 quarters. The position peaked at $37K in Q3 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- PNC Financial Services Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- PNC Financial Services Group sold 1,537 iTeos Therapeutics shares in Q3 2025, an estimated $15.3K.
- PNC Financial Services Group first reported a position in iTeos Therapeutics in Q1 2021 and held it in 15 quarters.
- PNC Financial Services Group's iTeos Therapeutics position peaked at $37K in Q3 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.